STOCK TITAN

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Syndax Pharmaceuticals (SNDX) grants inducement awards to new employees, offering up to 164,200 shares of common stock under the 2023 Inducement Plan.
Positive
  • None.
Negative
  • None.

WALTHAM, Mass., April 5, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on April 1, 2024 the Company granted inducement awards to purchase up to 164,200 shares of common stock to ten new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates.

About Syndax

Syndax is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include revumenib, a highly selective inhibitor of the Menin–KMT2A binding interaction, and axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. For more information, please visit www.syndax.com or follow the Company on X (formerly Twitter) and LinkedIn.

Syndax Contact

Sharon Klahre 
Syndax Pharmaceuticals, Inc. 
sklahre@syndax.com
Tel 781.684.9827 

Cision View original content:https://www.prnewswire.com/news-releases/syndax-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302107801.html

SOURCE Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals granted up to 164,200 shares of common stock to ten new employees.

The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months.

The inducement awards were granted under the Company's 2023 Inducement Plan.

Ten new employees received inducement awards from Syndax Pharmaceuticals.
Syndax Pharmaceuticals, Inc.

NASDAQ:SNDX

SNDX Rankings

SNDX Latest News

SNDX Stock Data

1.81B
84.63M
0.82%
106.63%
11.32%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
WALTHAM

About SNDX

syndax pharmaceuticals is a biotechnology company located at 35 gatehouse dr., building d, floor 3, waltham, ma 02451.